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Abstract 
Brain metastasis (BM) is infrequent in colorectal cancer (CRC) patients. Although BM from 
CRC is a late-stage phenomenon with an extremely poor prognosis, some subsets of patients 
would benefit from a multidisciplinary management strategy. The prognosis of patients with 
BM from CRC is associated with the curability of the therapy for BM and number of 
metastatic organs. The start of chemotherapy treatment usually requires a delay of about 4 
weeks after surgical resection in patients with primary CRC having synchronous distant 
metastasis. However, there is no evidence to indicate the required length of this delay 
interval. In addition, there is a chance that a patient may die because postoperative 
chemotherapy was not started soon enough and a metastatic tumor was able to develop 
rapidly. Here, we present a case where combination chemotherapy with capecitabine and 
oxaliplatin (XELOX) was started within 1 week after resection of BM from colon cancer for 
synchronous multiple liver metastases. To our knowledge, this is the first report of the start 
of chemotherapy, involving treatments such as folinic acid, fluorouracil, and oxaliplatin 
(FOLFOX); folinic acid, fluorouracil, and irinotecan (FOLFIRI); and XELOX within 1 week after 
resection of BM from colon cancer with synchronous multiple liver metastases. These 
findings suggest possible changes in the start time of chemotherapy after surgery in the 
future. 
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Introduction 
Brain metastasis (BM) is infrequent in colorectal cancer (CRC) patients. BM was 
diagnosed in 8.5% of patients in a recent cohort study; the cumulative incidence of BM 
after 5 years was estimated at 16.3% in patients with lung cancer, 9.8% in patients with 
renal cell carcinoma, 7.4% in patients with melanoma, 5.0% in patients with breast 
cancer and 1.2% in patients with CRC [1]. Although BM from CRC is a late-stage 
phenomenon with an extremely poor prognosis, some subsets of patients would benefit 
from a multidisciplinary management strategy. The prognosis of patients with BM from 
CRC is associated with the curability of the therapy for BM and number of metastatic 
organs [2]. 
Surgical resection of asymptomatic primary CRC with unresectable synchronous 
metastases is controversial. There is no doubt that, among patients with severe 
intestinal symptoms, resection is mandatory before starting systemic chemotherapy 
[3–5]. Palliative resection of the primary tumor is also reported to improve the efficacy 
of systemic chemotherapy [6] and prolong the duration of chemotherapy [7]. A recent 
review article suggested that non-curative resection of asymptomatic colorectal 
primary tumors may prolong survival in patients with metastatic CRC [8]. On the other 
hand, another article concluded that initial chemotherapy should be started, with 
resection of the primary tumor reserved for the small proportion of patients who 
develop major complications from the primary tumor, because resection of an 
asymptomatic primary tumor provides only minimal palliative benefit [9]. 
Surgical resection may delay the start of chemotherapy [10]. Generally, an interval of 
4 weeks is considered necessary after an operation until the beginning of 
chemotherapy treatments such as folinic acid, fluorouracil, and oxaliplatin (FOLFOX); 
folinic acid, fluorouracil, and irinotecan (FOLFIRI); and capecitabine and oxaliplatin 
(XELOX); however, there is no apparent evidence for this delay. A metastatic tumor can 
enlarge rapidly before the start of chemotherapy and possibly lead to patient death. 
Because the significance of the postoperative 4-week delay until the start of 
chemotherapy is not clear, we performed an early chemotherapy start in a patient who 
had undergone resection of BM from colon cancer for synchronous multiple liver 
metastases. 
Case Report 
A 62-year-old man was referred to our hospital with abdominal fullness and gait disturbance. 
Barium enema revealed a nearly obstructing tumor in the rectum (fig. 1). Stenosis prevented the 
endoscope from passing through. The patient needed a fasting because of the stenosis of the rectum. 
Abdominal computed tomography (CT) revealed more than 10 hepatic metastases (fig. 2a). Head CT 
and MRI showed a cerebellum metastasis (fig. 3). The patient underwent resection of BM and loop 
transverse colostomy. After surgery, the patient was allowed to drink water. On postoperative day 1, 
the patient was offered a meal. His postoperative recovery was uneventful. The patient strongly 
hoped for an early start of chemotherapy on postoperative day 5. Therefore, we started XELOX 
therapy on postoperative day 7 [oxaliplatin (130 mg/m2) on day 1 plus capecitabine (1,000 mg/m2) 
twice daily on days 1–14, every 3 weeks]. The patient was subsequently discharged in good condition 
on postoperative day 16. Gait disturbance was completely recovered 2 weeks after the treatment. 
XELOX + bevacizumab [BV (7.5 mg/kg) and oxaliplatin (130 mg/m2) on day 1 plus capecitabine 
(1,000 mg/m2) twice daily on days 1–14, every 3 weeks] was administered on postoperative day 28 
[11]. After 4 cycles of XELOX + BV, CT revealed a reduction in tumor size (fig. 2b). Laboratory studies  
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revealed a serum carcinoembryonic antigen level of 3,460 ng/ml, which improved to 936 ng/ml after 
4 cycles of chemotherapy. Observed adverse events that had appeared before were only a peripheral 
neuropathy in the acute stage (grade 1) and hand-foot syndrome (grade 1). Hematological toxicity, 
surgical site infection and incisional hernia were not noted. 
Tumor progression has not occurred for 4 months; the patient is now undergoing XELOX + BV 
therapy. 
Discussion 
Patients with BM from CRC have a poor prognosis because they often have 
substantial extracranial metastatic disease. Traditionally, the therapeutic goal in many 
of these patients has been to palliate debilitating neurologic symptoms, because most of 
these patients die of systemic disease. However, new advances in metastatic CRC 
management – including the incorporation of monoclonal antibody therapies BV [12], 
cetuximab [13], and panitumumab [14] – are enhancing the outcomes of patients with 
systemic disease. Although these targeted therapies have improved the management of 
systemic disease, they are not as effective for BM given the restrictions on delivery into 
a tumor caused by the blood-tumor and blood-brain barriers. In light of these advances, 
the management of BM from CRC may deserve reconsideration. 
It is fairly clear that careful patient selection influences the relative success of brain 
lesion resection. In a retrospective review from the late 1990s, Wronski and Arbit [15] 
evaluated the disease-specific outcomes of surgical resection in 73 patients with 
metastatic CRC to the brain who met specific criteria for surgery. The patients were 
evaluated for the extent of disease. Those with limited extracranial disease and a life 
expectancy in excess of 6 months were considered, as were those with a maximum of 2 
to 3 accessible lesions. 
Currently, the precise timing for starting treatment with chemotherapeutic agents 
prior to and/or after surgery in order to avoid postoperative complications is not clear, 
but an interval of at least 4 weeks has been suggested. In most clinical trials, patients 
who had undergone an operation within 4 weeks were excluded. In Benoist et al.’s 
study [10], the mean interval between diagnosis and chemotherapy start was 44 days 
in the resection group versus 15 days in the chemotherapy group. In this case, although 
the operation was performed, the interval between diagnosis and chemotherapy start 
was 14 days. Resection of the primary tumor significantly increases hospital stay and 
delays the initiation of chemotherapy; however, there is no evidence to suggest that 
this delay is associated with reduced response rates leading to curative resection or 
reduced survival. However, there is a chance that patients may die if they are not able 
to start chemotherapy because of the rapid postoperative progression of a metastatic 
tumor [16, 17]. We have reported a case of an early chemotherapy start in a patient 
who had undergone a right hemicolectomy for synchronous multiple liver metastases. 
And he survived for 22 months despite the huge liver metastases [18]. An early start of 
chemotherapy after surgery is desirable not only for primary CRC but also for the 
metastatic site. 
Resection of colorectal tumors with severe stenosis and bleeding is the first step of 
treatment in order to prevent the complications related to colorectal tumors. An early 
start of chemotherapy after surgery may be safe and improve the prognosis of colon  
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cancer patients with synchronous metastases. Prospective studies are needed to 
confirm the effect and safety of an early start of chemotherapy after surgery. We have 
already started a phase II trial to examine patients receiving an early start of 
chemotherapy. 
 
 
 
 
 
 
Fig. 1. Barium enema. The arrow indicates the nearly obstructing tumor. 
 
 
 
Fig. 2. Abdominal CT. a Imaging before chemotherapy: multiple liver metastases are noted by CT. 
b Imaging after 4 cycles of chemotherapy: CT revealed a reduction in tumor size. 
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Fig. 3. Head CT and MRI. Head CT and MRI showed a cerebellum metastasis. 
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